Calreticulin exposure increases cancer immunogenicity.
Clarke
Chris
C
Smyth
Mark J
MJ
D000818:Animals; D018943:Anthracyclines / Q000494:pharmacology / Q000627:therapeutic use; D000943:Antigens, Differentiation / Q000378:metabolism; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects / Q000276:immunology*; D037282:Calreticulin / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D018797:Cell Cycle Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D045744:Cell Line, Tumor; D002462:Cell Membrane / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D003713:Dendritic Cells / Q000276:immunology; D015180:Electrophoresis, Gel, Two-Dimensional; D005047:Etoposide / Q000494:pharmacology / Q000627:therapeutic use; D015151:Immunoblotting; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D016685:Mitomycin / Q000494:pharmacology / Q000627:therapeutic use; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism; D010587:Phagocytosis / Q000276:immunology; D054645:Protein Phosphatase 1; D021381:Protein Transport / Q000187:drug effects; D034622:RNA Interference; D011994:Recombinant Proteins / Q000494:pharmacology
D018943:Anthracyclines; D000943:Antigens, Differentiation; D000970:Antineoplastic Agents; D037282:Calreticulin; D018797:Cell Cycle Proteins; D011994:Recombinant Proteins; D016685:Mitomycin; D005047:Etoposide; C513256:Ppp1r15a protein, mouse; D054645:Protein Phosphatase 1